CASE REPORT

A case of secondary myelofibrosis in visceral leishmaniasis

  • YANG Mei ,
  • XIANG Baoyun ,
  • WEI Tao ,
  • CHI Yonge ,
  • LI Juan
Expand
  • The Fifth People’s Hospitol of Anyang (the Six Affiliated Hospital of Henan University of Science and Technology), Anyang 455000, Henan, China

Received date: 2024-02-24

  Revised date: 2024-05-10

  Online published: 2024-10-25

Abstract

The case was a 15-year-old male patient from Linzhou, Henan province and he was a student. Due to “intermittent fever for more than half a month”, he went to a local municipal hospital on March 3, 2021. The blood routine test showed leukocyte was 2.60 × 109/L, platelet was 65 × 109/L and hemoglobin was 113 g/L. He was diagnosed with infectious fever with leukothrombopenia and splenomegaly. After anti-infection treatment, the symptoms were improved and he was discharged home. But the condition sometimes recurred and he was admitted to the hematology department of a provincial hospital because of “repeated fever with fatigue and pancytopenia for more than 1 year” on April 19, 2022. The blood routine test showed white blood cell was 1.79 × 109/L, hemoglobin was 73 g/L and platelet was 54 × 109/L. Ultrasound showed enlarged lymphnodes in the neck and axilla, large liver and spleen with widened splenic veins. Bone marrow smear showed hyperplasia was active, granulocyte series reduced, erythrocyte series was significantly active while mature erythrocytes clustered and arranged in row, and no megakaryocyte was found in this smear. Bone marrow biopsy showed extensive fibrosis, increasing proportion of erythrocyte series, many megakaryocyte cells and also showed T cells were easy to be seen with scattered individual large cells. Positron emission tomography-computed tomography (PET-CT) showed diffuse active in splenic metabolism and no abnormalities in hepatic metabolism. Then the patient was suspected to have a splenic lymphoma and was transferred to surgery for splenectomy + abdominal lymph node dissection. Pathology of the spleen showed moderate histiocytic hyperplasia and pathogen in the cytoplasm of the histocyte which was verified Leishmania donovani by gene sequencing. Pathology of the spleen also showed extramedullary hematopoietic. The patient was diagnosed with visceral leishmaniasis. The patient had a history of contact with dogs and the county where he lived had visceral leishmaniasis case report. He was admitted to the Fifth People’s Hospital of Anyang in June 27, 2022 and was began to be treated with sodium stibogluconate injection from that time. The admission examination showed emaciation, malnutrition and hepatomegaly that liver could be palpated 10cm below costal margin on right midclavicular line, moderate quality, no tenderness. Blood routine test showed that the white blood cell was 11.17 × 109/L, hemogloubin was 104 g/L and platelet was 245 × 109/L. The result of rK39 kala-azar detect rapid test was positive. Abdominal CT showed a significantly enlarged liver. After treated with sodium stibogluconate injection for 1 course (0.6 g/d, 9 d), The temperature returned to normal and the general condition improved, but Leishmania amastigote was visible in his bone marrow smear. So another course sodium stibogluconate injection (0.6 g/d, 9 d) was given to him. After the second course’s treatment, the bone marrow smear was reexamined and no Leishmania amastigote could be found. The paitent was recovered and discharged home. He felt well and the abdominal CT showed liver was somewhat reduced and bone marrow trephine biopsy performed had returned to normal and bone marrow smear was not found Leishmania amastigote about 10 months after initiation of the therapy.

Cite this article

YANG Mei , XIANG Baoyun , WEI Tao , CHI Yonge , LI Juan . A case of secondary myelofibrosis in visceral leishmaniasis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2024 , 42(5) : 684 -687 . DOI: 10.12140/j.issn.1000-7423.2024.05.021

References

[1] Zhou ZB, Pan GQ, Li YY, et al. Prevalence of visceral leishmaniasis in China in 2021[J]. Chin J Parasitol Parasit Dis, 2023, 41(2): 149-155. (in Chinese)
  (周正斌, 潘改芹, 李元元, 等. 2021年我国内脏利什曼病疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(2): 149-155.)
[2] Li YY, Zhou ZB, Yang LM, et al. Epidemiological characteristics of visceral leishmaniasis in China in 2022[J]. Chin J Parasitol Parasit Dis, 2023, 41(6): 669-676. (in Chinese)
  (李元元, 周正斌, 杨丽敏, 等. 2022年全国内脏利什曼病疫情特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(6): 669-676.)
[3] Song SH, Gui XE. Follow-up of a patient with Leishmania and human immunodeficiency virus co-infection who received prolonged sodium stibogluconate treatment[J]. Chin J Parasitol Parasit Dis, 2018, 36(2): 148-152. (in Chinese)
  (宋世会, 桂希恩. 葡萄糖酸锑钠长疗程治疗1例利什曼原虫与人类免疫缺陷病毒合并感染患者的追踪观察[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 148-152.)
[4] Jia XX, Deng CQ. A case of visceral leishmaniasis misdiagnosed as liver cirrhosis induced by hepatitis C[J]. Chin J Parasitol Parasit Dis, 2023, 41(6): 776-779. (in Chinese)
  (贾晓霞, 邓春青. 误诊为丙型病毒性肝炎肝硬化的内脏利什曼病1例[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(6): 776-779.)
[5] Wu YQ, Meng JX, Zhang XN, et al. A case of hemophagocytic syndrome caused by kala-azar and literature review[J]. J Clin Hematol, 2017, 30(1): 71-72. (in Chinese)
  (武永强, 孟君霞, 张晓南, 等. 黑热病引起噬血细胞综合征1例并文献复习[J]. 临床血液学杂志, 2017, 30(1): 71-72.)
[6] Jia ZZ, Liu HY, Jiang Q, et al. A case of visceral leishmaniasis misdiagnosed as a hematological disorder[J]. Chin J Parasitol Parasit Dis, 2023, 41(2): 257-259. (in Chinese)
  (贾枕枕, 刘洪英, 江琦, 等. 误诊为血液病的内脏利什曼病1例[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(2): 257-259.)
[7] Lu DQ, Wu WQ, Zhou M, et al. One case report of hemophagocytic syndrome secondary to leishmaniasis[J]. Chin J Infect Chemother, 2023, 23(5): 630-632. (in Chinese)
  (陆丹倩, 吴为强, 周梅, 等. 黑热病继发噬血细胞综合征1例[J]. 中国感染与化疗杂志, 2023, 23(5): 630-632.)
[8] Lang BJ, Hu YC, Zhou XG, et al. Clinical pathological analysis of 3 cases of visceral leishmaniasis[J]. Chin J Clin Exp Pathol, 2021, 37(4): 472-474. (in Chinese)
  (郎博娟, 胡余昌, 周小鸽, 等. 内脏利什曼病3例临床病理分析[J]. 临床与实验病理学杂志, 2021, 37(4): 472-474.)
[9] Leukemia and Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and treatment of primary myelofibrosis (2019)[J]. Chin J Hematol, 2019, 40(1): 1-7. (in Chinese)
  (中华医学会血液学分会白血病淋巴瘤学组. 原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J]. 中华血液学杂志, 2019, 40(1): 1-7.)
[10] Huang Y, Sun JF, Yang J, et al. Morphology of bone marrow in patients with secondary myelofibrosis and primary myelofibrosis and its clinical significance[J]. J Shanxi Med Univ, 2012, 43(6): 453-456, 481. (in Chinese)
  (黄艳, 孙嘉峰, 杨佳, 等. 继发性与原发性骨髓纤维化骨髓组织形态学观察及临床意义[J]. 山西医科大学学报, 2012, 43(6): 453-456, 481.)
[11] Suvajdzi? N, Pavlovi? M, Misi? S, et al. Secondary myelofibrosis in visceral leishmaniasis: case report[J]. Haematologia, 2001, 31(2): 167-171.
[12] Rocha Filho FD, Ferreira FV, Mendes FDEO, et al. Bone marrow fibrosis (pseudo-myelofibrosis) in human kala-azar[J]. Rev Soc Bras Med Trop, 2000, 33(4): 363-366.
[13] Schwartz T, Jensenius M, Blomberg B, et al. Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients[J]. Trop Dis Travel Med Vaccines, 2019, 5: 16.
[14] Dhingra KK, Gupta P, Saroha V, et al. Morphological findings in bone marrow biopsy and aspirate smears of visceral kala-azar: a review[J]. Indian J Pathol Microbiol, 2010, 53(1): 96-100.
[15] Kumar PV, Vasei M, Sadeghipour A, et al. Visceral leishmaniasis: bone marrow biopsy findings[J]. J Pediatr Hematol Oncol, 2007, 29(2): 77-80.
Outlines

/

〈 〉